Vaccination does more than protect people from infectious diseases. It reduces healthcare spending, prevents premature deaths, keeps children in school, and helps families avoid the financial consequences of serious illness. For governments managing limited healthcare budgets, immunization offers a way to improve population health while supporting long-term economic development.
The financial benefits can be substantial. A study published in Health Affairs estimated that every dollar invested in immunization against 10 infectious diseases in 94 low- and middle-income countries would generate approximately $20 in economic benefits between 2021 and 2030. When researchers included a broader monetary valuation of lives saved, the estimated return exceeded $50 per dollar invested.
These estimates depend on the economic methods used, but both approaches indicate that vaccination can produce benefits well beyond its initial costs.
As countries face rising healthcare expenditures, competing public health priorities, and persistent inequalities in access to medical services, understanding the cost-effectiveness of vaccines is increasingly important.
How Vaccination Reduces Healthcare Costs
Treating infectious diseases can require hospitalization, medication, laboratory testing, rehabilitation, and long-term medical care. Severe infections may also cause permanent disabilities that require continued support.
Vaccination helps prevent many of these expenses by reducing the likelihood of infection or serious illness, depending on the vaccine.
For example, measles vaccination prevents a highly contagious disease that can cause pneumonia, brain inflammation, and death. Hepatitis B vaccination helps prevent chronic infection that can eventually lead to cirrhosis and liver cancer. Vaccines against Haemophilus influenzae type b (Hib) reduce the risk of serious bacterial infections, including meningitis and pneumonia.
These benefits extend beyond individual patients. When vaccination reduces disease transmission, it can also lower the number of people requiring treatment and help protect those who are particularly vulnerable to infection.
A 2024 study published in The Lancet estimated that vaccination against 14 diseases prevented approximately 154 million deaths worldwide between 1974 and 2024. About 101 million of those lives saved were infants younger than one year.
Researchers also estimated that vaccination contributed to 40% of the global decline in infant mortality during that period.
What Makes a Vaccine Cost-Effective?
A vaccine is considered cost-effective when the health benefits it produces justify the resources required to deliver it, relative to other available uses of healthcare funding.
Researchers generally evaluate several factors, including the price of the vaccine, the cost of administering it, the number of people protected, and the burden of disease prevented.
One widely used measure is the disability-adjusted life year (DALY). A DALY represents one year of healthy life lost because of premature death or disability.
When an intervention prevents disease, it can avert DALYs, meaning that people collectively experience more years of healthy life.
For example, if a vaccination programme costs $100,000 more than the alternative and prevents the loss of 2,000 healthy life years, its incremental cost would be $50 per DALY averted.
Illustrative cost-effectiveness calculation
| Measure | Illustrative figure |
|---|---|
| Additional programme cost | $100,000 |
| Healthy life years saved | 2,000 |
| Incremental cost ÷ DALYs averted | $50 per DALY averted |
This is a hypothetical example, not an estimate for a particular vaccine.
A lower cost per DALY averted generally indicates better value, provided that the analyses use comparable assumptions.
However, cost-effectiveness does not automatically mean affordability. A programme may deliver excellent long-term value while still requiring more immediate funding than a government can provide.
Earlier health economic assessments often compared the cost per DALY averted with a country’s gross domestic product (GDP) per person. Some analyses classified interventions costing less than one or three times GDP per capita as cost-effective.
Such thresholds are no longer considered sufficient as stand-alone decision rules. Researchers emphasize that funding decisions must also account for local healthcare priorities, available resources, alternative interventions, and the consequences of diverting spending from other essential services.
The Economic Benefits of Immunization
The financial value of vaccination extends far beyond the direct cost of treating an infectious disease.
When people remain healthy, they are more likely to attend school, participate in the workforce, and contribute to their communities. Parents and caregivers also lose fewer working days caring for sick family members.
Researchers generally distinguish between direct savings in healthcare expenditure and broader economic gains related to productivity, survival, and quality of life.
A comprehensive economic evaluation published in 2020 examined immunization against 10 pathogens across 94 low- and middle-income countries.
The analysis projected the following returns for vaccination investments made during 2021–2030:
| Economic evaluation method | Estimated benefit per $1 invested |
|---|---|
| Cost-of-illness approach | $19.80 |
| Value-of-a-statistical-life approach | $52.20 |
Source: Health Affairs, 2020. Figures are modeled estimates for 2021–2030, not observed returns from completed programmes.
The cost-of-illness approach captures economic losses avoided through vaccination, including reduced medical spending and lost productivity.
The value-of-a-statistical-life approach assigns a monetary value to reductions in the risk of death. It produces larger estimates because it includes benefits that extend beyond direct financial savings.
Neither estimate should be interpreted as the amount of money governments will immediately recover in their budgets. Instead, these calculations help demonstrate the broader economic importance of preventing infectious diseases.
Which Vaccines Provide Important Health and Economic Benefits?
Different vaccines protect against different health risks. Their cost-effectiveness depends on local disease prevalence, vaccine prices, population characteristics, healthcare costs, and the ability of health systems to deliver immunization services.
The following vaccines illustrate how preventive healthcare can reduce both immediate illness and long-term medical needs.
| Vaccine | Diseases or complications prevented | Potential economic benefits |
|---|---|---|
| Measles | Measles, pneumonia, encephalitis, and related deaths | Fewer outbreaks and hospital admissions |
| Polio | Poliomyelitis and paralysis | Reduced disability-related costs and long-term care |
| Diphtheria, tetanus, and pertussis (DTP) | Severe bacterial infections and their complications | Lower medical costs and fewer premature deaths |
| Tuberculosis (BCG) | Severe forms of childhood tuberculosis | Reduced costs associated with serious childhood disease |
| Hepatitis B | Hepatitis B infection, cirrhosis, and liver cancer | Lower long-term treatment and cancer-related costs |
| Hib | Meningitis, pneumonia, and other invasive bacterial infections | Fewer hospitalizations and disability-related expenses |
| Pneumococcal | Pneumonia, meningitis, and invasive pneumococcal disease | Lower costs for severe respiratory and bloodstream infections |
| Rotavirus | Severe diarrheal disease | Fewer hospital admissions and dehydration treatments |
| Human papillomavirus (HPV) | Cervical cancer and other HPV-related diseases | Reduced cancer treatment costs and premature mortality |
These benefits are not identical across countries or age groups. A vaccine that provides exceptional economic value in an area with high disease incidence may produce a different return where the disease is uncommon.
The design of national vaccination schedules therefore requires an assessment of local needs rather than a universal ranking based on vaccine price alone.
Global Vaccination Coverage in 2025
Although vaccines prevent millions of deaths, access remains uneven.
According to estimates published by the World Health Organization (WHO) and UNICEF in July 2026, approximately 110 million infants received all three recommended doses of a diphtheria, tetanus, and pertussis-containing vaccine in 2025.
This represented 85% of infants globally, leaving many children without complete protection.
An estimated 13.5 million infants received no routine vaccinations during their first year of life. Another approximately 6 million received some vaccinations but did not complete the recommended DTP series.
UNICEF, WHO
+1
These figures demonstrate that even vaccines included in national immunization programmes do not necessarily reach everyone who needs them.
The challenge is particularly important in low-income countries, remote communities, and areas affected by armed conflict or disrupted healthcare services.
Improving coverage requires more than purchasing vaccines. Governments must also invest in the infrastructure and healthcare workers needed to deliver them reliably.
Why Vaccine Prices Do Not Tell the Whole Story
A relatively inexpensive vaccine can become costly to deliver when healthcare facilities are far apart, refrigeration systems are unreliable, or trained personnel are unavailable.
Conversely, a vaccine with a higher purchase price may still represent good economic value if it prevents expensive treatment, long-term disability, or premature death.
This distinction matters when governments consider introducing new vaccines or expanding existing programmes.
The full cost of vaccination includes the vaccine itself, transportation, storage, healthcare worker time, administration supplies, recordkeeping, safety monitoring, and efforts to reach underserved populations.
A study published in Value in Health estimated that immunization programmes covering 10 vaccines in 94 low- and middle-income countries would cost approximately $70.8 billion over 2011–2030.
Vaccine procurement accounted for about 53% of the estimated total, while delivery accounted for approximately 47%. The small remainder related to stockpiles.
The findings show why comparisons based only on the price of individual doses can be misleading.
Financing Immunization in Low-Income Countries
Countries with constrained public budgets face difficult decisions about healthcare spending. Hospitals, essential medicines, maternal health services, sanitation, and disease prevention all compete for funding.
Nevertheless, preventive interventions can reduce future pressure on health systems, particularly where infectious diseases account for a substantial share of illness and mortality.
WHO expenditure data published in October 2025 provide an indication of the resources devoted to vaccine procurement.
Across 140 countries, annual spending on vaccines for routine immunization averaged $1.30 per person during 2021–2023, or approximately $76 per surviving infant.
The expenditure represented about 0.3% of current healthcare spending and 0.02% of GDP in the countries analyzed. These figures cover vaccine expenditure, not the complete cost of delivering immunization programmes.
Long-term financing matters because immunization services must operate continuously. Interruptions in vaccine procurement, healthcare staffing, or distribution can leave new generations of children unprotected.
For governments, sustainable financing may require incorporating immunization into routine healthcare budgets, improving purchasing efficiency, and strengthening existing primary healthcare services.
However, increasing vaccination spending should not automatically come at the expense of other essential interventions. The objective is to allocate limited resources in ways that achieve the greatest feasible improvements in population health.
How Governments Can Evaluate Vaccination Investments
National vaccination policies should reflect the disease burden, financial circumstances, and healthcare infrastructure of each country.
Economic assessments are most useful when they combine evidence about vaccine performance with information about the population that would receive it.
Important considerations include:
Disease burden: How common is the disease, and how frequently does it cause hospitalization, disability, or death?
Vaccine effectiveness: How much protection does vaccination provide under real-world conditions?
Programme costs: What are the combined expenses of purchasing, distributing, storing, and administering vaccines?
Healthcare savings: What treatment expenses and other economic losses could vaccination prevent?
Population coverage: How many people can realistically receive the recommended doses?
Equity: Will the programme improve access for populations facing the greatest barriers to healthcare?
Cost-effectiveness studies should also examine uncertainty. Disease incidence, vaccine prices, and delivery costs can change, potentially altering the results.
Local evidence is particularly valuable because estimates from one country cannot always be applied directly to another.
A vaccination programme may be highly cost-effective in a region with frequent outbreaks but less economically attractive in a setting where disease incidence is already extremely low.
The Future of Cost-Effective Vaccination
The range of diseases preventable through immunization has expanded considerably since the first large-scale childhood vaccination programmes were established.
Vaccines against hepatitis B, Hib, pneumococcal disease, rotavirus, and HPV have become important components of preventive healthcare. Malaria vaccines have also been introduced in an increasing number of African countries.
By the end of 2025, WHO reported that malaria vaccines had been introduced at national or subnational level in 25 African countries.
The global expansion of HPV vaccination represents another important development. HPV vaccines can prevent infections responsible for most cases of cervical cancer, offering substantial health benefits that may not become fully apparent until decades after vaccination.
WHO estimates that global coverage with at least one HPV vaccine dose among girls increased from 17% in 2019 to 33% in 2025. However, coverage remains far below the international target of vaccinating 90% of girls by age 15.
+1
These developments also highlight an important feature of vaccine economics: benefits can accumulate over long periods.
Hepatitis B vaccination given during infancy, for example, may prevent chronic liver disease and cancer many years later. HPV vaccination offers similar long-term preventive benefits against several cancers.
Therefore, short-term budget assessments may underestimate the total value of immunization unless they account for future health outcomes.
Why Immunization Remains a Public Health Priority
Vaccination is not universally cost-saving, and the economic value of individual vaccines varies by country, disease, age group, and delivery strategy.
Nevertheless, decades of research demonstrate that well-designed vaccination programmes can produce major health improvements at costs that compare favorably with many other medical interventions.
Their benefits extend beyond preventing infection. By reducing mortality, disability, healthcare spending, and lost productivity, vaccines can also contribute to stronger households and more resilient economies.
The evidence indicates that decisions about immunization should consider not only what governments must spend today but also what preventable disease will cost populations in the future.
For countries seeking to improve health outcomes while managing limited resources, maintaining effective vaccination programmes and improving access to recommended vaccines remain important long-term investments.
References
The following sources support the updated figures and analysis.
Bertram MY, et al. (2016). Cost-effectiveness thresholds: pros and cons. Bulletin of the World Health Organization.
Shattock AJ, et al. (2024). Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. The Lancet, 403, 2307–2316.
Sim SY, et al. (2020). Return on investment from immunization against 10 pathogens in 94 low- and middle-income countries, 2011–30. Health Affairs.
Portnoy A, et al. (2021). Costs of immunization programs for 10 vaccines in 94 low- and middle-income countries from 2011 to 2030. Value in Health.
World Health Organization (2026). Immunization coverage: Global estimates for 2025.
World Health Organization and UNICEF (2026). Global childhood immunization coverage inches forward despite conflict and hesitancy.
World Health Organization (2025). Situation Analyses of Immunization Expenditures: Key Facts, 2024.